1. Immunology/Inflammation
  2. PD-1/PD-L1
  3. MS1-96

MS1-96 is an orally active PD-L1 (programmed death-ligand 1) degrader. MS1-96 effectively reduced PD-L1 protein levels across multiple colorectal cancer (CRC) cell lines. MS1-96 directly binds to PD-L1 (KD = 2.58 μM) and enhances the interaction between HIP1R and PD-L1, thereby altering the intracellular trafficking of PD-L1 within clathrin-coated vesicles. MS1-96 induces abnormal N-glycosylation of PD-L1, destabilizing the protein and hastening its lysosome-mediated degradation. MS1-96 can be used for the study of colorectal cancer.

For research use only. We do not sell to patients.

MS1-96

MS1-96 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

MS1-96 is an orally active PD-L1 (programmed death-ligand 1) degrader. MS1-96 effectively reduced PD-L1 protein levels across multiple colorectal cancer (CRC) cell lines. MS1-96 directly binds to PD-L1 (KD = 2.58 μM) and enhances the interaction between HIP1R and PD-L1, thereby altering the intracellular trafficking of PD-L1 within clathrin-coated vesicles. MS1-96 induces abnormal N-glycosylation of PD-L1, destabilizing the protein and hastening its lysosome-mediated degradation. MS1-96 can be used for the study of colorectal cancer[1].

IC50 & Target

PD-L1

2.58 μM (Kd)

In Vitro

MS1-96 (10 μM, 48 h) significantly reduces PD-L1 protein levels in RKO cells but shows no reduction in PD-L1 mRNA levels in RKO cells[1].
MS1-96 (0-3 μM, 0-48 h) induces PD-L1 degradation in RKO cells in a time- and dose-dependent manner[1].
MS1-96 (1.5 μM, 24 h) reduces the level of PD-L1 on the surface of RKO and LoVo cells[1].
MS1-96 (1.5 μM, 24 h) disrupts the PD-1/PD-L1 interaction by downregulating PD-L1 in RKO and LoVo cells[1].
MS1-96 (1.5 μM, 24 h) enhances the killing effect of T cells on RKO cells and reduced the number of surviving cells[1].
MS1-96 (1.5 μM, 24 h) increases LDH release in RKO cells following co-culture with activated PBMCs, indicating enhanced cytotoxicity[1].
MS1-96 (1.5 μM, 0-12 h) promotes the degradation of PD-L1 in existing RKO cells, rather than inhibiting translation, thus reducing PD-L1 levels[1].
MS1-96 (1.5 μM) degrades PD-L1 in RKO cells via the lysosomal pathway, independent of proteasomes or autophagy[1].
MS1-96 induces aberrant N-glycosylation of PD-L1 at N35, N192, N200, and N219 sites in RKO cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

MS1-96 (0-400 mg/kg, p.o., once daily for 10 days) effectively inhibits colorectal cancer tumor growth in MC38 cell xenograft mice by downregulating PD-L1 that was strictly dependent on CD8+ T cells, with a good safety profile[1].
MS1-96 (0-400 mg/kg, p.o., once daily for 9 days) fails to inhibit MC38 tumor growth in immunodeficient MC38 cell xenograft mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice (female, 5 weeks old) were subcutaneously inoculated with 8 × 105 MC38 colorectal cancer cells[1].
Dosage: 0 mg/kg, 100 mg/kg, 200 mg/kg, 400 mg/kg
Administration: P.o., once daily for 8, 10 days
Result: The drug significantly inhibited the growth of MC38 tumors in a dose-dependent manner.
Tumor volume and weight were significantly reduced.
No significant change in mouse body weight indicated good drug tolerance.
Western blot analysis showed a significant decrease in PD-L1 protein levels in tumor tissues.
Depletion of CD8+ T cells alone or simultaneous depletion of CD4+ and CD8+ T cells had no anti-tumor effect.
Depletion of CD4+ T cells alone did not affect the anti-tumor effect.
Animal Model: Immunodeficient nude mice (female, 4 weeks old) were subcutaneously inoculated with 8 × 105 MC38 colorectal cancer cells[1].
Dosage: 0 mg/kg, 200 mg/kg, 400 mg/kg
Administration: P.o., once daily for 9 days
Result: Failed to inhibit the growth of MC38 tumors.
Molecular Weight

375.50

Formula

C25H29NO2

SMILES

O=C(NC1=CC(CC[C@]2([H])[C@]3([H])CC[C@@]4(C)[C@@]2([H])CC[C@@H]4O)=C3C=C1)C5=CC=CC=C5

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MS1-96
Cat. No.:
HY-179558
Quantity:
MCE Japan Authorized Agent: